Dr Hermann Hauser, serial entrepreneur, co-founder of Amadeus Capital Partners and founder of semiconductor company, Arm Ltd, and gene-sequencing company, Solexa / Illumina, joins as chair of the ...
A reliable supply of consistent and physiologically relevant motor neurons is fundamental to the study and screening of potential treatments for motor neuron diseases ioMotor Neurons also offer an ...
BlueRock Therapeutics, a clinical-stage cell therapy company, and bit.bio, a synbio firm, signed a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T ...
Restructuring the pricing of bit.bio’s human cells is expanding access across the life sciences sector, enabling scientists in academia, biotech, and pharma to adopt new approach methodologies (NAMs) ...
The report provides evidence-based metrics aligned with the UN Sustainable Development Goals (SDGs), highlighting year-over-year improvements. It demonstrates how sustainability is integrated across ...
Synthego, a provider of genome editing solutions, and bit.bio, a synthetic biology firm, said that they are expanding their strategic partnership to work on a platform for implementing synthetic ...
Bit Bio, the new startup that pitches itself as the "enter button for the keyboard to the software of life," only needed three weeks to raise its latest $41.5 million round of funding. Originally ...
Automata, a leading robotics and automation company powering life sciences labs, today announced it is partnering with bit.bio, to automate a key aspect of the manufacturing process of their iPSC ...
CAMBRIDGE, England, Dec. 2, 2025 /PRNewswire/ -- bit.b io, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability Report, reaffirming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results